NO20043457L - 3- (imidazolyl) -2-alkoxypropanoic acids as TAFIA inhibitors - Google Patents
3- (imidazolyl) -2-alkoxypropanoic acids as TAFIA inhibitorsInfo
- Publication number
- NO20043457L NO20043457L NO20043457A NO20043457A NO20043457L NO 20043457 L NO20043457 L NO 20043457L NO 20043457 A NO20043457 A NO 20043457A NO 20043457 A NO20043457 A NO 20043457A NO 20043457 L NO20043457 L NO 20043457L
- Authority
- NO
- Norway
- Prior art keywords
- imidazolyl
- tafia inhibitors
- alkoxypropanoic
- acids
- alkoxypropanoic acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0201389A GB0201389D0 (en) | 2002-01-22 | 2002-01-22 | 3-(imidazolyl)-2-alkoxypropanoic acids |
| GB0202027A GB0202027D0 (en) | 2002-01-29 | 2002-01-29 | 3-(imidazolyl)-2-alkoxypropanoic acids |
| PCT/IB2003/000060 WO2003061652A1 (en) | 2002-01-22 | 2003-01-10 | 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20043457L true NO20043457L (en) | 2004-08-19 |
Family
ID=27614792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043457A NO20043457L (en) | 2002-01-22 | 2004-08-19 | 3- (imidazolyl) -2-alkoxypropanoic acids as TAFIA inhibitors |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1467731A1 (en) |
| JP (1) | JP2005520811A (en) |
| KR (1) | KR20040077775A (en) |
| CN (1) | CN1620291A (en) |
| AP (1) | AP2004003084A0 (en) |
| AR (1) | AR038197A1 (en) |
| BR (1) | BR0307016A (en) |
| CA (1) | CA2472238A1 (en) |
| EA (1) | EA200400716A1 (en) |
| EC (1) | ECSP045200A (en) |
| HR (1) | HRP20040659A2 (en) |
| IL (1) | IL162677A0 (en) |
| IS (1) | IS7310A (en) |
| MA (1) | MA27167A1 (en) |
| MX (1) | MXPA04006573A (en) |
| NO (1) | NO20043457L (en) |
| OA (1) | OA12756A (en) |
| PA (1) | PA8563501A1 (en) |
| PE (1) | PE20030929A1 (en) |
| PL (1) | PL371487A1 (en) |
| TN (1) | TNSN04121A1 (en) |
| TW (1) | TW200302094A (en) |
| UY (1) | UY27615A1 (en) |
| WO (1) | WO2003061652A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005051384A1 (en) * | 2003-11-25 | 2005-06-09 | Pfizer Limited | Stabilised pharmaceutical compositions |
| EP1874322A1 (en) * | 2005-04-18 | 2008-01-09 | Bayer Schering Pharma Aktiengesellschaft | Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci |
| JPWO2010050525A1 (en) | 2008-10-29 | 2012-03-29 | 大正製薬株式会社 | Compound having TAFIa inhibitory activity |
| US8987242B2 (en) | 2008-12-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | Morpholinone compounds as factor IXA inhibitors |
| US8642582B2 (en) | 2008-12-05 | 2014-02-04 | Merck Sharp & Dohme Corp. | Morpholinone compounds as factor IXa inhibitors |
| SG182767A1 (en) * | 2010-03-18 | 2012-08-30 | Daiichi Sankyo Co Ltd | Cycloalkyl-substituted imidazole derivative |
| ES2608779T3 (en) | 2010-03-18 | 2017-04-17 | Daiichi Sankyo Company, Limited | Cyclopropanecarboxylic acid derivative |
| JP6461113B2 (en) | 2013-06-10 | 2019-01-30 | サノフイＳａｎｏｆｉ | Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and use as pharmaceuticals |
| CN108883094A (en) | 2016-03-29 | 2018-11-23 | 第三共株式会社 | Inflammatory bowel Remedies for diseases in association |
| SG11202002322TA (en) | 2017-09-14 | 2020-04-29 | Daiichi Sankyo Co Ltd | Compound having cyclic structure |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9901572D0 (en) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| ES2334101T3 (en) * | 2000-08-17 | 2010-03-05 | Pfizer Limited | IMIDAZOLS REPLACED AS TAFIA INHIBITORS. |
-
2003
- 2003-01-10 JP JP2003561596A patent/JP2005520811A/en active Pending
- 2003-01-10 AP APAP/P/2004/003084A patent/AP2004003084A0/en unknown
- 2003-01-10 MX MXPA04006573A patent/MXPA04006573A/en unknown
- 2003-01-10 WO PCT/IB2003/000060 patent/WO2003061652A1/en not_active Application Discontinuation
- 2003-01-10 EA EA200400716A patent/EA200400716A1/en unknown
- 2003-01-10 BR BR0307016-6A patent/BR0307016A/en not_active IP Right Cessation
- 2003-01-10 IL IL16267703A patent/IL162677A0/en unknown
- 2003-01-10 CA CA002472238A patent/CA2472238A1/en not_active Abandoned
- 2003-01-10 EP EP03700059A patent/EP1467731A1/en not_active Withdrawn
- 2003-01-10 CN CNA03802599XA patent/CN1620291A/en active Pending
- 2003-01-10 KR KR10-2004-7011370A patent/KR20040077775A/en not_active Application Discontinuation
- 2003-01-10 OA OA1200400190A patent/OA12756A/en unknown
- 2003-01-10 PL PL03371487A patent/PL371487A1/en unknown
- 2003-01-16 TW TW092100889A patent/TW200302094A/en unknown
- 2003-01-17 PE PE2003000058A patent/PE20030929A1/en not_active Application Discontinuation
- 2003-01-20 UY UY27615A patent/UY27615A1/en not_active Application Discontinuation
- 2003-01-21 AR ARP030100165A patent/AR038197A1/en unknown
- 2003-01-22 PA PA20038563501A patent/PA8563501A1/en unknown
-
2004
- 2004-06-14 IS IS7310A patent/IS7310A/en unknown
- 2004-06-30 TN TNP2004000121A patent/TNSN04121A1/en unknown
- 2004-07-15 MA MA27786A patent/MA27167A1/en unknown
- 2004-07-19 HR HR20040659A patent/HRP20040659A2/en not_active Application Discontinuation
- 2004-07-22 EC EC2004005200A patent/ECSP045200A/en unknown
- 2004-08-19 NO NO20043457A patent/NO20043457L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003061652A1 (en) | 2003-07-31 |
| CA2472238A1 (en) | 2003-07-31 |
| PA8563501A1 (en) | 2004-08-31 |
| AP2004003084A0 (en) | 2004-09-30 |
| PE20030929A1 (en) | 2003-11-05 |
| MA27167A1 (en) | 2005-01-03 |
| EP1467731A1 (en) | 2004-10-20 |
| IS7310A (en) | 2004-06-14 |
| OA12756A (en) | 2006-07-03 |
| KR20040077775A (en) | 2004-09-06 |
| EA200400716A1 (en) | 2004-12-30 |
| CN1620291A (en) | 2005-05-25 |
| MXPA04006573A (en) | 2004-10-04 |
| BR0307016A (en) | 2004-11-03 |
| UY27615A1 (en) | 2003-08-29 |
| WO2003061652A8 (en) | 2004-09-10 |
| HRP20040659A2 (en) | 2004-10-31 |
| IL162677A0 (en) | 2005-11-20 |
| AR038197A1 (en) | 2005-01-05 |
| PL371487A1 (en) | 2005-06-13 |
| TW200302094A (en) | 2003-08-01 |
| ECSP045200A (en) | 2004-08-27 |
| TNSN04121A1 (en) | 2006-06-01 |
| JP2005520811A (en) | 2005-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2016042I1 (en) | NEW HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMAS INHIBITORS | |
| NO20050665L (en) | Pyrrolidone derivatives as MAOE inhibitors | |
| DK1482932T3 (en) | N3-alkylated benzimidazole derivatives as MEK inhibitors | |
| DK1492785T3 (en) | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | |
| DK1663232T3 (en) | Benzimidazole derivatives as human chymase inhibitors | |
| DK1586319T3 (en) | Thiadiazolidinones as GSK-3 inhibitors | |
| DK1311488T3 (en) | Substituted imidazoles as tafia inhibitors | |
| DK1789041T3 (en) | Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors | |
| NO20055680D0 (en) | Hexahydropyridoisoquinolines as DPP-IV inhibitors | |
| DK1797042T3 (en) | Indozolone derivatives as 11B-HSD1 inhibitors | |
| DE60320933D1 (en) | RHO-KINASE INHIBITORS | |
| ATE505471T1 (en) | AZAINDOL KINASE INHIBITORS | |
| NO20043642L (en) | Heterocyclic tripeptides such as hepatitis C inhibitors | |
| NO20044654L (en) | Piperidinoylpiperidines as 5-HTIF agonists | |
| DK1585749T3 (en) | Diazepinoindole derivatives as kinase inhibitors | |
| DE602004018837D1 (en) | PTIDASE-IV INHIBITORS | |
| HK1101823A1 (en) | Imidazole derivatives used as tafia inhibitors | |
| ATA2602002A (en) | PACKAGING | |
| NO20043457L (en) | 3- (imidazolyl) -2-alkoxypropanoic acids as TAFIA inhibitors | |
| DE60301419D1 (en) | packaging | |
| NO20043610L (en) | Phenylpyrimidinamines as IgE inhibitors | |
| ZA200405344B (en) | 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors. | |
| DE50310603D1 (en) | splitter basement | |
| PT102805B (en) | COLAPSAVEL PACKAGING | |
| UA7498S (en) | WRAPPER FOR LOAVONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |